Insider Buying: Opko Health Inc. (OPK) VP Purchases 6,000 Shares of Stock

Opko Health Inc. (NASDAQ:OPK) VP Steven D. Rubin bought 6,000 shares of the stock in a transaction on Wednesday, March 7th. The stock was purchased at an average price of $3.25 per share, with a total value of $19,500.00. Following the completion of the purchase, the vice president now owns 5,691,915 shares of the company’s stock, valued at $18,498,723.75. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Opko Health Inc. (NASDAQ OPK) traded up $0.27 during trading hours on Friday, hitting $3.59. 5,870,000 shares of the stock traded hands, compared to its average volume of 5,310,000. Opko Health Inc. has a 1-year low of $2.66 and a 1-year high of $8.54. The company has a quick ratio of 0.98, a current ratio of 1.14 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $2,010.00, a P/E ratio of -8.98 and a beta of 1.59.

How to Become a New Pot Stock Millionaire

Several large investors have recently bought and sold shares of the company. Xact Kapitalforvaltning AB acquired a new stake in shares of Opko Health during the fourth quarter worth $179,000. Delek Group Ltd. acquired a new stake in shares of Opko Health during the fourth quarter worth $382,000. Meitav Dash Investments Ltd. acquired a new stake in shares of Opko Health during the fourth quarter worth $347,000. Belpointe Asset Management LLC raised its holdings in shares of Opko Health by 30.0% during the fourth quarter. Belpointe Asset Management LLC now owns 110,500 shares of the biotechnology company’s stock worth $541,000 after purchasing an additional 25,500 shares during the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. raised its holdings in shares of Opko Health by 18.0% during the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 340,326 shares of the biotechnology company’s stock worth $1,668,000 after purchasing an additional 51,890 shares during the last quarter. Institutional investors and hedge funds own 22.71% of the company’s stock.

Several equities research analysts have recently commented on the stock. BidaskClub downgraded shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Wednesday, January 10th. Zacks Investment Research downgraded shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Friday, February 9th. JPMorgan Chase & Co. downgraded shares of Opko Health from a “neutral” rating to an “underweight” rating and set a $7.00 price objective for the company. in a research note on Friday, March 2nd. Finally, ValuEngine downgraded shares of Opko Health from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Four research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $13.25.

COPYRIGHT VIOLATION WARNING: This story was first reported by Markets Daily and is the property of of Markets Daily. If you are viewing this story on another publication, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this story can be read at https://www.themarketsdaily.com/2018/03/11/insider-buying-opko-health-inc-opk-vp-purchases-6000-shares-of-stock.html.

About Opko Health

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Insider Buying and Selling by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply